EU to support novel antibiotics with €20 million funding
BioVersys will receive €20 million in funding to support its development of new treatments for antimicrobial resistant infections.
List view / Grid view
BioVersys will receive €20 million in funding to support its development of new treatments for antimicrobial resistant infections.
Recarbrio (imipenem-cilastatin and relebactam) was approved for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).